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Polycomb group (PcG) proteins are key epigenetic
regulators of hematopietic stem cell (HSC) fate. The
PcGmembers Ezh2 and Ezh1 are important determi-
nants of embryonic stem cell identity, and the tran-
script levels of these histone methyltransferases
are inversely correlated during development. How-
ever, the role of Ezh1 in somatic stem cells is largely
unknown. Herewe show that Ezh1maintains repopu-
lating HSCs in a slow-cycling, undifferentiated state,
protecting them from senescence. Ezh1 ablation
induces significant loss of adult HSCs, with concom-
itant impairment of their self-renewal capacity due
to a potent senescence response. Epigenomic and
gene expression changes induced by Ezh1 deletion
in senesced HSCs demonstrated that Ezh1-medi-
ated PRC2 activity catalyzes monomethylation and
dimethylation of H3K27. Deletion of Cdkn2a on the
Ezh1 null background rescued HSC proliferation
and survival. Our results suggest that Ezh1 is an
important histonemethyltransferase for HSCmainte-
nance.
INTRODUCTION
Epigenetic regulation of chromatin structure is thought to con-
trol cell memory, and Polycomb group (PcG) proteins are impor-
tant components of diverse epigenetic phenomena, including
genomic imprinting, cell fate determination, stem-cell plasticity
and renewal, and cancer development (Goldberg et al., 2007).
PcG-mediated epigenetic alteration of hematopoietic stem cells
(HSCs) is considered a driving force behind many age-related
HSC changes and is often dysregulated in human malignancies
(Sauvageau and Sauvageau, 2010). Protection of the transcrip-
tional ‘‘stemness’’ network is thus essential for the maintenance
of a healthy HSC compartment throughout life. However, little isCellknown about how epigenetic mechanisms dictate the activities
of Polycomb factors to ensure blood homeostasis.
PcG proteins assemble in multimeric complexes and induce
transcriptional repression of target genes through chromatin
changes such as methylation of lysine 27 on histone 3 (H3K27).
Biochemical analysis revealed that PcG proteins assemble in at
least two complexes, Polycomb repressive complexes 1 and 2
(PRC1 and PRC2). Studies of mouse mutants showed that these
factors are essential for normal development, with deletion of
Polycomb genes resulting in prenatal or early postnatal death,
depending on inactivated gene and how the inactivation is
achieved (Sauvageau andSauvageau, 2010). ThePRC2complex
contains one of two homologous enhancer of zeste (Ez) pro-
teins (Ezh1 or Ezh2), which contain near identical catalytic SET
domains (Laible et al., 1997). Ezh1 andEzh2 are chromatin-modi-
fying histone lysine methyltransferases (Margueron and Rein-
berg, 2011). Most research on H3K27 has focused on the
trimethylated form (H3K27me3), while the monomethylated and
dimethylated forms (H3K27me1 and H3K27me2, respectively)
remain poorly characterized (Margueron and Reinberg, 2011).
Although Ezh2 knockout in embryonic stem cells (ESCs) reduces
H3K27 dimethylation and trimethylation, H3K27 methylation at
PcG target promoters is not abolished. This has been attributed
to the activity of Ezh1, which forms an alternative PRC2 com-
plex (Shen et al., 2008) and has distinct chromatin-binding prop-
erties (Margueron et al., 2008). The importance of the H3K27me3
mark has been characterized through conditional targeting of
Ezh2 in somatic stem cells in the brain, pancreas, epidermis,
and hematopoietic system (Chen et al., 2009; Ezhkova et al.,
2009; Mochizuki-Kashio et al., 2011; Pereira et al., 2010; Su
et al., 2003). Double knockout of Ezh1 and Ezh2 in mouse skin
abolishes the H3K27me3 modification and severely compro-
mises formation and maintenance of hair follicles (Ezhkova
et al., 2011). However, the role of PRC2-Ezh1 in themaintenance
of HSCs is unknown.
Cell senescence is a permanent cell-cycle arrest that is re-
fractory to growth factors and other proliferation signals. Un-
like apoptotic cells, which rapidly disintegrate, senescent cells
remain viable in long-term culture and are found with increasing
frequency in aged tissues and at sites of age-related pathology,Stem Cell 11, 649–662, November 2, 2012 ª2012 Elsevier Inc. 649
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Figure 1. Characterization of Primitive Hematopoietic Populations in Ezh1-KO Mice
(A) Expression of total Ezh2 and Ezh1 mRNA was measured by qRT-PCR in sorted bone marrow (BM) subpopulations from young (8-week-old) and aged
(50-week-old) WT mice: lineage negative (Lin); Lin, Sca1+, c-Kit+ (LSK); long-term repopulating HSCs (LSKCD34lowFlk-2low; LT-HSCs), myeloid progenitors
(LinKit+Sca1; MPs), and common lymphoid progenitors (LinKitlowSca1lowCD127+; CLPs). Results are standardized to b-actin and are expressed as the fold
change of the indicated subpopulations from aged mice compared with the same gated subpopulations from young mice (means ± SD; n = 12, *p < 0.05).
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HSC Senescence Protection by Ezh1including preneoplastic lesions. Cells senesce in response to
many potentially oncogenic stressors, including severe DNA
damage, dysfunctional telomeres, chromatin alterations, oxida-
tive stress, and strong mitogenic signals such as those delivered
by some oncogenes (Collado et al., 2007). Induction of the
senescence program normally requires activation of tumor sup-
pressor pathways, including the p19ARF (p14ARF in humans), p53,
and RB-p16INK4a signaling cascades, and the senescence pro-
gram is now regarded as a potent cell-autonomous barrier to
tumorigenesis (Prieur and Peeper, 2008). Accordingly, loss of
the senescence response increases the incidence of cancer in
humans and mice (Nardella et al., 2011). Moreover, cell se-
nescence also entails increased secretion of proinflammatory
proteins, inducing the senescence-associated (SA) secretory
phenotype (SASP), and might contribute significantly to chronic
inflammation (Freund et al., 2010).
Epigenetic mechanisms play an important role in senescence.
In senescing human fibroblasts, heterochromatic regions con-
dense to form senescence-associated heterochromatic foci
that limit the DNA damage response (Di Micco et al., 2011; Narita
et al., 2003). Expression of Jhdm1b, a demethylase specific for
the H3K36me2 modification, causes cell immortalization or
leukemic transformation depending on its demethylase activity
on p15INK4b, and its knockdown results in cell senescence (He
et al., 2008). In human and mouse fibroblasts, the Cdkn2a region
(encoding p16INK4a and ARF) is repressed by PcG-mediated
H3K27me3, and the repressive mark is lost during oncogene-
induced senescence, resulting in Cdkn2a expression (Bracken
et al., 2007).
The incomplete loss of H3K27me3 in Ezh2/ ESCs, the rela-
tively mild phenotypes of tissues lacking Ezh2, and the inverse
expression patterns of Ezh1 and Ezh2 during development
together suggest that Ezh1- and Ezh2-mediated H3K27 methyl-
ation are differentially coordinated during tissue development
and homeostasis. It is therefore important to determine the role
of Ezh1-containing PRC2 complexes in HSC maintenance. We
report here that Ezh1 is essential for adult hematopoiesis through(B) Representative western blots (WBs) showing the expression of Ezh1, Ezh2, S
(50-week-old) WT mice.
(C) Top: Ezh1 genomic locus and the Ezh1-targeted locus before and after Cre-m
enzyme-digested DNA fragments recognized by the 30and 50 probes are indicate
both ckoEzh1+/+ and ckoEzh1fl/+ ESCs hybridized with the 30and 50 probes (left pa
are shown in the right panels. See also Table S1.
(D) qRT-PCR analysis of the mRNA expression of Ezh1, p16INK4a, ARF, and E
standardized to b-actin levels, and are expressed as the fold change of the indic
n = 12, **p < 0.001, *p < 0.05). See also Table S2.
(E) Representative WBs showing the protein levels of Ezh1, Ezh2, H3K27me3, H
Ezh1-KO and Control mice.
(F) Histological and immunostaining characterization of paraffin-embedded BM
eosin staining (H&E), and anti-Ki67 and anti-Ezh1 antibodies. Scale bars represe
(G) Representative FACS profiles of BM cells from Ezh1-KOmice and Control litter
markers, c-Kit and Sca1. FACS plots were gated on the LSK supopulation (orang
percentages of MPPs, LT-HSCs, and ST-HSCs, and for expression of CD150+ an
(green gate) was gated on LKlowSlowCD127+. Myeloid progenitors, defined as th
myeloid progenitors (CMPs), granulocytic macrophage progenitors (GMPs), and
expression. At least five mice per genotype were tested, over at least two separa
population, except for the subclassification of LSK cells, where numbers indicat
(H and I) Absolute numbers per femur of LSK, LT, ST, MPP, and LSK-SLAM pri
described in Figure 1G) in BM from Control and Ezh1-KO mice.
Data are means ± SD (n = 10, *p < 0.05, **p < 0.001). See also Figure S1.
Cellthe regulation of histone H3K27methylation. Our results indicate
that Ezh1 promotes a slow cycling state in primitive HSCs and
prevents differentiation and senescence of adult HSCs.
RESULTS
Expression of the Histone Methyltransferase Ezh1
Increases during HSC Aging
Since expression of several PcG genes involved in chromatin
organization becomes dysregulated during the aging of HSCs
(Chambers et al., 2007b), we hypothesized that histone methyl-
transferase activity might be coordinately distributed between
Ezh1 and Ezh2 in young and old HSC populations. Ezh1 and
Ezh2 mRNAs were detected in primitive long-term HSCs (LT-
HSCs) isolated from the bone marrow (BM) of young (8-week-
old) wild-type C57BL/6 mice; but while levels of Ezh1 mRNA
were 3-fold higher in LT-HSCs isolated from BM of 50-week-
old mice, Ezh2 transcript levels did not change with age (p <
0.05; Figure 1A). A similar divergence was seen with protein
expression (Figure 1B), as noted in other studies on human
and mouse HSCs (Mochizuki-Kashio et al., 2011; Wagner
et al., 2009) and mouse kidney (Margueron et al., 2008). Protein
levels of the other PRC2 components, Suz12 and Eed, did not
change with age (Figure 1B). Given this pattern of Ezh1 expres-
sion in repopulating HSCs, we hypothesized that Ezh1 might act
primarily as a homeostatic regulator of HSCs.
To test this, we generated a conditional knockout Ezh1 allele in
which exons encoding the SET catalytic domain were flanked
with loxP sequences (ckoEzh1fl/fl) (Figure 1C). To induce spe-
cific Ezh1 deletion in the hematopoietic system, we crossed
ckoEzh1fl/fl mice with vavCre transgenic mice. From here on,
Ezh1fl/fl-vavCretg/+ knockout mice and their Ezh1fl/fl-vavCre+/+
wild-type (WT) littermates are referred to as Ezh1-KO and
Control. Analysis of primitive HSCs (LSKCD150+CD48; 20-
week-old) showed that complete Ezh1 deletion correlated with
increased expression of p16INK4a, ARF, and p15INK4b (p <
0.001), whereas expression of Ezh2 was unaffected (Figure 1D).uz12, Eed, and b-actin in HSCs (LSK cells) from young (8-week-old) and aged
ediated recombination. Red arrows mark the loxP sequences. The restriction
d. Bottom: Southern blots show HindIII-digested genomic DNA isolated from
nels). Genomic PCR analysis of ckoEzh1+/+, ckoEzh1fl/fl, and ckoEzh1fl/+ mice
zh2 in HSCs (LSKCD150+CD48) from Ezh1-KO and Control mice. Data are
ated subpopulation from Ezh1-KO mice relative to Control mice (means ± SD;
3K27me2, H3K27me1, and histone3 (H3) in HSCs (LSKCD150+CD48) from
sections from Ezh1-KO mice and Control littermates, using hematoxylin and
nt 500 and 50 mm for H&E and 100 mm for immunohistochemistry.
mates. BM cells were immunostained with antibodies to hematopoietic lineage
e gate), which was subclassified for expression of CD34 and CD135 to give the
d CD48 to give the percentage of the LSK-SLAM population. The CLP fraction
e LK+S (LKS) population (MP, blue gate), were subclassified into common
megakaryocytic-erythroid progenitors (MEPs) based on CD16/32 and CD34
te experiments. Numbers indicate percentages of the total nucleated BM cell
e the percentage of the total LSK subpopulation.
mitive populations (H), and CLP, CMP, MEP, and GMP subpopulations (I) (as
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Figure 2. Ezh1 Deletion Induces Cellular Senescence
(A and B) Average chimerism in posttransplant competitive recipients transplanted with 1:1 ratios of donor and competitor cells, analyzed by the contribution of
donor-derived (CD45.2) cells to peripheral blood (PB) cells (A), and the indicated subclassified LSK populations (B). FACS plots show a representative experi-
ment. The bar graphs show the percentages of the indicated populations 12 weeks posttransplant. Data are means ± SD (n = 8, *p < 0.05, **p < 0.001). See also
Figure S2.
(C) Percentage of early apoptotic cells (annexinV-Hoechst staining) in the indicated populations. Data are means ± SD (n = 6, *p < 0.05).
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Cell Stem Cell
HSC Senescence Protection by Ezh1The overall level of H3K27me3 was not altered in Ezh1-KO
mice; however, the levels of H3K27me2 and H3K27me1 were
markedly lower (Figure 1E).
Ezh1 Deletion Causes BM Failure
We next examined the effect of Ezh1 deficiency on primitive
HSC subpopulations in BM. Immunostaining for Ezh1 in BM
sections revealed specific vavCre-mediated Ezh1 deletion in
hematopoietic cells, while fibrovascular stroma (sinusoid endo-
thelial cells and fibroblasts) remained positive, a finding also
reflected in weak Ezh1 protein expression in whole Ezh1-KO
BM (Figure 1F; data not shown). Histological analysis detected
severe femoral hypoplasia in BM of adult Ezh1-KO mice (Fig-
ure 1F), reflecting a 2-fold lower BM cellularity than in Controls
(p < 0.001; Figure S1A available online). Nonlymphoid tissues
showed no significant differences in Ezh1 staining between
genotypes (Figure S1B). Furthermore, adult Ezh1-KO animals
had a smaller HSC-enriched LSK pool than Controls (p <
0.05; Figures 1G and 1H). Analysis of LSK subfractions in
Ezh1-KO mice showed significantly lower frequencies (p <
0.001) and absolute numbers (p < 0.001) of all three primi-
tive repopulating LSK populations: LT-HSCs, short-term HSCs
(ST-HSCs), and multipotent progenitors (MPPs) (Figures 1G
and 1H). Further enrichment of the LSK population with SLAM
markers (CD48 and CD150+) confirmed reduction of the
LSK-SLAM population in Ezh1-KO BM (p < 0.001; Figures 1G
and 1H).
The more mature lymphoid progenitor pool was also signifi-
cantly smaller in KO mice (p < 0.05; Figures 1G and 1I), while
frequencies and numbers of myeloid progenitors and colony-
forming cells (CFCs) were unaffected (Figure 1I and Figure S1C).
Moreover, pyrorin Y staining of LSK CD34low cells showed a
smaller pool of quiescent (G0) HSCs in Ezh1-KO mice (p <
0.05; Figure S1D). Analysis of BM cells for the side popula-
tion (SP) phenotype, a marker of quiescent HSCs in adult BM,
revealed 2-fold fewer SP cells in Ezh1-KO mice (p < 0.05;
Figure S1E).
To determine the long-term reconstitution capacity of Ezh1-
deficient BM cells, we crossed the ckoEzh1fl/fl line with
Rosa26Cre-ERT2 mice to generate Rosa26Cre-ERtg/tg;Ezh1fl/fl
(Ezh1-KO-ER) and Rosa26Cre-ERtg/tg;Ezh1+/+ (Control-ER)
mice. After tamoxifen induction of Cre-mediated Ezh1 deletion,
BM cells from these mice were used in competitive transplanta-
tion experiments, thus excluding influence from the Ezh1-defi-
cient BM microenvironment on hematopoiesis. Donor-derived
(CD45.2) Ezh1-KO-ER BM cells did not contribute significantly
to peripheral blood (PB) at 12 weeks posttransplant (wpt; p <
0.05; Figure 2A) or LSKs in BM at 16 wpt (p < 0.001; Figure 2B).
Moreover, KO donor cells contributed weakly to lymphoid pro-
genitors in BM (p < 0.05; Figure S2A). These results are consis-(D) Proliferation rate of LSK, MP, and CLP subpopulations measured by in vivo B
(E) Left: Percentage of senescence-associated b-gal (SA-b-gal) positive cells de
Control and Ezh1-KOmice. Fluorescence histograms for C12-fluorescein show th
the median fluorescence intensities of the respective populations. Right: Percen
means ± SD (n = 6, *p < 0.05, **p < 0.001). See also Figure S2.
(F) Cytochemical staining of SA-b-gal activity in paraffin sections of BM from C
paraffin-embedded BM sections from Control and Ezh1-KO mice immunostaine
Scale bars, 50 mm. See also Figure S2.
Celltent with a requirement for Ezh1 in the self-renewal and mainte-
nance of adult HSCs.
HSC Senescence Is Increased in Ezh1-KO BM
Analysis of freshly isolated primitive stem- and progenitor-cell
BM populations revealed no difference between genotypes in
the frequency of annexinV+/Hoechst cells, indicating that pro-
grammed cell death does not underlie the disappearance of
Ezh1-KO LSK HSCs from the BM or their inability to compete
with WT cells in transplantation experiments (Figure 2C). We
therefore analyzed whether Ezh1 deletion affects the prolifera-
tion of primitive hematopoietic cells in vivo. Examination of
cell-cycle status by BrdU incorporation, normalized for total
numbers, showed that the LT- and ST-HSC/MPP Ezh1-KO pop-
ulations cycled less than corresponding Controls (p < 0.05; Fig-
ure 2D and data not shown).
Given that hematopoietic-specific Ezh1 inactivation trig-
gered accumulation of transcripts for p16INK4a and ARF (Fig-
ure 1D), which are critical activators of the senescence pro-
gram (Lowe et al., 2004), we tested whether Ezh1 deletion
triggered cellular senescence in HSCs. Consistent with the anti-
senescence role of other Polycomb proteins such as Bmi1
(Jacobs et al., 1999), depletion of endogenous Ezh1 in isolated
mouse embryonic fibroblasts (MEFs) resulted in increased tran-
script and protein expression of p16INK4a and ARF (p < 0.001;
Figure S2B), as well as increased activity of senescence-
associated SA-b-galactosidase (SA-b-gal) (Figure S2C). Con-
versely, reexpression of Ezh1 should recapitulate the immortal-
ization phenotype of p16INK4a/ARF null MEFs (Gonzalez et al.,
2006). Evaluation of this in colony-formation assays in Ezh1-
deleted MEFs confirmed that Ezh1 reexpression immortalizes
fibroblasts by downregulating expression of p16INK4a and ARF
(Figure S2C).
These in vitro results suggested that adult Ezh1-KO BM might
have a senescent phenotype. To test this in vivo, we first
measured SA-b-gal activity in primitive HSC subpopulations
by FACS-based assay using the fluorogenic substrate C12FDG
(Debacq-Chainiaux et al., 2009). Approximately 34% of Ezh1-
KO LT-HSCs were positive for SA-b-gal, comparable to Ras-
induced MEF senescence (Kuilman et al., 2010), while fewer
than 7% of HSCs from Control littermates stained positive (p <
0.001) (Figure 2E and Figure S2D). In contrast, the frequency
of MPP senescence was similar in WT and Ezh1-KO BM (Fig-
ure 2E). We also examined SA-b-gal activity and DNA damage
by immunohistochemistry in BM sections. Immunostaining for
gH2AX DNA repair foci revealed activation of the DNA-damage
response in Ezh1-BM mice (Figure 2F), consistent with recent
evidence linking DNA damage to cellular senescence (Di Micco
et al., 2011). Immunostaining also revealed greater expression
of Dcr2, p15INK4b, and p16INK4a in Ezh1-KO BM, whereasrdU incorporation over 24 hr. Data are means ± SD (n = 5, *p < 0.05).
termined by flow cytometry in LSK, LT, ST, and MPP primitive populations in
e relative levels of b-gal in LSK subpopulations; the values above the peaks are
tage of SA-b-gal-positive cells in LSK, LT, ST, and MPP populations. Data are
ontrol and Ezh1-KO mice, and accompanying panels showing representative
d with the indicated antibodies.
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Figure 3. Characterization of Primitive
Hematopoietic Populations in Ezh1-KO
Mice
(A) vavCre expression in a sagittal section of
an E11.5 Rosa26-eYFPtg/+/vavCretg/+ embryo.
Expression is detected in most hematopoietic
cells and organs. YFP-positive cells are brown
and sections were hematoxylin counterstained.
The right panel shows an enlarged view of the
fetal liver (FL) area.
(B) Absolute cell numbers in whole FLs from
Control and Ezh1-KO mice at E11.5 (n = 12).
(C) Left: Representative FACS profiles of FL cells
from Ezh1-KO mice and Control littermates were
gated on the LSK subpopulation; the CLP fraction
was gated on LKlowSlowCD127+, and myeloid
progenitors were defined as the LKS population
(MP). Numbers indicate percentages of the
total nucleated BM cell subpopulations. At least
eight mice per genotype were tested, over at
least two separate experiments. Right: Absolute
numbers per FL of LSK, MP, and CLP primitive
populations are indicated. Data are means ± SD
(n = 16, *p < 0.05).
(D) Recipient mice were injected with pooled FL
cells from Ezh1-KO mice or Control littermates
(CD45.2). Average chimerism in posttransplant
recipients: values on the right panels are the
mean percentages of donor-derived (CD45.2)
lymphoid (B220) cells 8 weeks after secondary
transplant. FACS plots show a representative
experiment (n = 6).
(E) SA-b-gal-positive cell content in transplanted
chimeras harboring FL cells from Control or Ezh1-
KO mice, determined by flow cytometry of LSK,
CLP, and MP primitive populations. Top: C12-
fluorescein fluorescence histograms show the
relative levels of b-gal in LSK subpopulations;
values above the peaks are the median fluores-
cence intensities of the respective populations
(n = 6). Bottom: Percentages of SA-b-gal-positive
cells in LSK, MP, and CLP populations. Data are
means ± SD (n = 6; bottom panel).
(F) Representative cytochemical staining of SA-
b-gal-positive cells on BM paraffin sections.
Scale bars, 50 mm.
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HSC Senescence Protection by Ezh1expression of Bmi1 and Ezh2 was the same in Control and
Ezh1-KO BM (Figure 2F). RT-PCR analysis confirmed greater
expression of the senescence markers Dcr2, p15INK4b, and
Dec1 (Collado and Serrano, 2006) in Ezh1-KO LSKCD150+
cells (Figure S2E). To confirm the role of Ezh1 in hematopoie-
sis, we retrovirally reexpressed Ezh1 in Ezh1-KO-ER HSCs
(LSKCD150+) and examined the ability of these cells to res-
cue hematopoiesis in competitive transplantation experiments.
Ezh1 overexpression substantially decreased p16INK4a expres-
sion in LSKCD150+ cells but had no effect on Ezh2 levels (Fig-
ure S2F). In the transplantation experiments, restored Ezh1
expression rescued the capacity of donor Ezh1-KO cells to
engraft (Figure S2G). Moreover, mice engrafted with these cells
were protected from the accumulation of senescent LSK
cells observed in recipients of vector-overexpressing Ezh1-KO
cells (p < 0.05; Figure S2H). These results suggest a primary func-
tion of Ezh1 in the protection of adult HSCs from senescence.654 Cell Stem Cell 11, 649–662, November 2, 2012 ª2012 Elsevier InEzh1 Is Not Required for Fetal Hematopoiesis
Ezh2 appears to be required only in fetal HSCs, since its deletion
does not compromise adult hematopoiesis except for lympho-
poiesis (Mochizuki-Kashio et al., 2011; Su et al., 2003). To inves-
tigate the requirement of Ezh1 during fetal hematopoiesis, we
first tested the specificity of vavCre activity in fetal liver (FL) by
crossing vavCretg/+ mice with Rosa26-eYFPtg/ mice. Consistent
with previous studies (Stadtfeld and Graf, 2005), immunohisto-
chemistry revealed constitutive vav-promoter-driven Cre ex-
pression in hematopietic cells from E9.5, mostly restricted to
FL (Figure 3A). Total FL cell numbers in mutant mice were indis-
tinguishable from those of Control littermates (Figure 3B). How-
ever, FL of mutant mice contained lower proportions of all
primitive FL-LSK cells (p < 0.05; Figure 3C). In repopulation
experiments, Ezh1-deficient and Control FL cells showed only
a slight difference in the ability to reconstitute the lymphoid-con-
taining (B220) population in PB (Figure 3D). Analysis of SA-b-galc.
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HSC Senescence Protection by Ezh1expression in E12.5 FL by FACS and cytochemical staining did
not show accumulation of senescent FL cells of either genotype
(Figures 3E and 3F). These data thus suggest that while Ezh1
deletion in FL influences HSC number, Ezh1 is not required for
maintenance of fetal hematopoiesis.
Ezh1 Deficiency Impairs B Cell Development
Given the differences in primitive subpopulations in Ezh1-KO
mice, we analyzed whether specific Ezh1 deletion affects adult
hematopoiesis in vivo. PB cell counts and flow cytometry of
spleen and thymus in Ezh1-KO animals revealed marked and
significant loss of B lymphocytes (p < 0.05) and a slight drop
in myeloid cells (Figures 4A–4C). Ezh1-KO spleens were about
half the size of spleens from Control littermates (p < 0.05; Fig-
ure 4B), consistent with the reduced proportion of mature
lymphoid cells (p < 0.05; Figure 4B). Histopathological analysis
of Ezh1-KO spleen mice was consistent with this phenotype
(Figure 4D). Hematoxylin and eosin staining showed manifest
white and red pulp hypoplasia and an absence of germinal
centers in Ezh1-KO spleen, accompanied by lymphoid cell
depletion. Analysis of Ezh1-deficient BM cells showed altered
development of pro-B cells (IgMB220+CD43+), pre-B cells
(IgMB220+CD43), and immature B cells (IgM+B220+CD43),
with a concomitantly reduced proportion of recirculating lym-
phoid cells (IgM+B220highCD43) (p < 0.05; Figure 4E). The
alterations in B cell development indicate that Ezh1 is required
for proper differentiation of HSCs into lymphoid progeny, and
raise the possibility that PRC2-Ezh1 restricts certain HSC/pro-
genitor activities, similar to the impaired B cell maturation from
pro-B to pre-B cells observed in mice lacking Ezh2 (Su et al.,
2003).
BM Failure upon Loss of Ezh1 Is Hematopoietic Cell
Autonomous
To define the impact of Ezh1 on the maintenance of the stem cell
pool, we performed sequential BM transplantations. BM from
Ezh1-KO or WT littermate mice (CD45.2) was injected into irradi-
ated CD45.1 hosts, which were monitored for reconstitution of
PB, spleen, and BM. Ezh1-KO cells showed significantly weaker
PB chimerism at 4 wpt (p < 0.05; Figure S3A), as well as less
engraftment of primitive HSCs at 16 wpt (p < 0.05; Figure S3B).
PB lymphoid cell counts were significantly lower in Ezh1-KO-in-
jected hosts than in control-injected counterparts (p < 0.05; Fig-
ure 5A). Donor-derived CD45.2+ BM cells were then purified and
injected into secondary recipients. Spleens of secondary recipi-
ents showed a consistent decrease in the lymphoid-containing
(B220) population (p < 0.05; Figure 5B). Moreover, the senes-
cence phenotype was far more marked in secondary recipients
of Ezh1-KO cells than in secondary recipients of Control BMcells
(Figure 5C). Strikingly, Ezh1/ HSCs were unable to engraft ter-
tiary recipients, while recipients of Control cells survived (data
not shown).
Ezh1 Deletion Results in Homing Defects in BM Cells
To evaluate the mechanism of action of Ezh1 loss on HSC
engraftment, we assessed the homing capacity of CFSE-labeled
Ezh1-KO and Control HSCs in transplantation assays. CFSE+
Ezh1-KO LSK cells homed to the BM of recipient mice at a lower
frequency than cells from Control mice (p < 0.05; Figure 5D).CellComparable results were obtained by injecting tamoxifen-
treated Ezh1-KO-ER HSCs (CD45.2) into CD45.1 hosts (p <
0.05; Figure S3C). The retention of Ezh1-deficient HSCs in
the BM niche was examined by reciprocal transplant experi-
ments in which WT donor BM cells (CD45.1) were transplanted
into tamoxifen-treated Control-ER or Ezh1-KO-ER recipients
(CD45.2). Analysis of recipient PB and immunohistochemical
staining of paraffin BM sections revealed no differences in
engraftment between the genotypes (Figures 5E and 5F), indi-
cating that an Ezh1-deficient microenvironment does not affect
HSC engraftment. Together, our transplantation experiments
demonstrate that the development of Ezh1/-induced senes-
cence is hematopoietic cell autonomous, with defective migra-
tion of HSCs to the BM that likely compromises their self-
renewal.
Regulation of Multipotency Genes by Ezh1
To investigate the mechanism by which Ezh1 deletion impairs
HSC activity, we profiled gene expression in highly enriched re-
populating HSCs (LSKCD150+CD48) isolated from Ezh1-KO
and Control mice. Stringent gene array analysis identified 788
differentially expressed genes in Ezh1-KOHSCs (297 downregu-
lated and 491 upregulated; Table S4). A complete list of these
genes has been deposited in the Gene Expression Omnibus,
accession number GSE36288. The downregulated genes in-
cluded many crucial for HSC function, such as Gata3, Runx1,
Meis1, Myb, Pten, Foxo3a, Thy1.1, Abcg2, Srgap2, Pbx1, and
Cdkn1a (Chambers et al., 2007a; Forsberg et al., 2010). Also
downregulated were genes for essential lymphoid differentiation
factors (Ng et al., 2009; Oguro et al., 2010), such as Dntt, Flk2,
Igh6, Ikaros, Sfpi1, and Mef2c, and cell-cycle related genes
such as Cdc6, Cdk1, andMcm5, suggesting growth arrest (Kuil-
man et al., 2010) (Figures S4A and S4B). The set of upregulated
genes included genes related to secreted proteins and differen-
tiation/development (e.g., Bmp2 and Igfbp3), consistent with the
central role of secreted factors in senescence (Kang et al., 2011).
Moreover, there was robust upregulation of genes encoding
proinflammatory factors associated with SASP, including IL-6,
IL-7, granulocyte macrophage colony-stimulating factor (GM-
CSF), and certain insulin-like growth factor (IGF)-binding pro-
teins (Coppe´ et al., 2010) (Figures 6B and 6C). These findings
suggest that Ezh1 controls the secretome by repressing secre-
tion of key senescence factors. Furthermore, we detected
altered expression of genes regulated by other Polycomb
members, including upregulated expression of Dkk2, Cyp1b1,
Vsnl1, and Il6R, and downregulated expression of H2Afx,
Gmnn, and Foxc1 (Bracken et al., 2006; Majewski et al., 2008)
(Figures 6B and 6C). The genes differentially regulated in Ezh1-
depleted cells were objectively classified by Gene Ontology
analysis (Figure 6A). Changes in expression for several genes
from each category were validated by real-time PCR using
sorted HSCs (LSKCD150+CD48 cells) from Ezh1-KO and
Control mice (Figure 6B), confirming the array analysis.
We next conducted chromatin immunoprecipitation (ChIP)
experiments on sorted Ezh1-KO and WT HSCs (LSKCD150+
cells) to detect the effect of Ezh1 deletion on H3K27 methyla-
tion and the specific binding of Ezh1, Ezh2, and Bmi1 to the
promoter regions of Ezh1 target genes. Lack of Ezh1 increased
the amount of bound H3K27me2 in the promoter regions of theStem Cell 11, 649–662, November 2, 2012 ª2012 Elsevier Inc. 655
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Figure 4. Lymphoid Differentiation Defects in Ezh1-KO Hematopoiesis
(A) Peripheral blood counts in 20- to 22-week-old Ezh1-KO and Control mice. WBC, white blood cells; LYM, lymphocytes; MID, monocytes; GRA, granulocytes;
RBC, red blood cells; PLT, platelets. Data are means ± SD (n = 8, *p < 0.05).
(B) Top: Representative FACS plots showing the percentages of lymphoid (B220) andmyeloid (Ly6G and F4/80) positive cells in the Ezh1-KO andControl spleens.
Bottom: Bar charts show absolute numbers of total spleen, lymphoid, andmyeloid cell populations in the spleens of Ezh1-KO and Control mice; data aremeans ±
SD (n = 11, *p < 0.05). The photograph shows representative spleens from Ezh1-KO and Control mice.
(C) Left: Representative FACS plots showing the percentages of CD4-positive, CD4+CD8-positive, and CD8-positive cells in the thymus of Ezh1-KO and Control
animals. Right: The photograph shows thymus from Ezh1-KO andControl mice, and the bar charts show thymus cell populations and absolute numbers ofmature
lymphoid (CD4, CD4+CD8, and CD8) cells. Data are means ± SD (n = 10).
(D) Histological (H&E) and immunostaining (anti-Ki67 antibody) characterization of representative spleen sections from Ezh1-KO mice and Control littermates.
Scale bars, 1,000 mm (upper panels) and 200 mm (magnified views in lower panels).
(E) Left: Representative FACS plots showing the percentages of pro-B cells (IgMB220+CD43+), pre-B cells (IgMB220+CD43), immature B cells (IgM+
B220+CD43), and recirculating cells (IgM+B220highCD43) in Ezh1-KO and Control BM. Right: Absolute numbers per femur of mature lymphoid cell populations
in Ezh1-KO and Control mice. Data are means ± SD (n = 12, *p < 0.05).
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Figure 5. Ezh1 Function in Hematopoiesis Is Cell Autonomous
(A) Average chimerism in posttransplant secondary recipients (separated by a 10-week reconstitution period) analyzed for the contribution of donor-derived
(CD45.2) cells to circulating mature myeloid cells (Mac-1/Gr-1), macrophages (F4-80), granulocytes (LY6G), and lymphoid subfractions (CD3, CD4, CD8, and
B220). Data are means ± SD (n = 8; *p < 0.05). See also Figure S3.
(B) Subpopulation profiles of B cells (B220; CD45.1/CD45.2) in spleens of secondary recipient mice transplanted with BM cells from Ezh1-KO mice or Control
littermates. The bar chart shows the percentages (mean ± SD) of the indicated populations (n = 8; *p < 0.05).
(C) Cytochemical staining of SA-b-gal-positive cells in paraffin-fixed BM sections of recipient mice transplanted with BM cells from Ezh1-KO mice or Control
littermates. Scale bars, 50 mm.
(D) Representative FACS plots of BM cells in recipient mice 24 hr after injection with CFSE-labeled Control or Ezh1-KO LSK cells. The bar chart shows themean ±
SD of two independent experiments with four mice per experiment (n = 8; *p < 0.05). See also Figure S3.
(E) H&E and anti-Ki67 staining of BM sections of Control-ER and Ezh1-KO-ER recipient mice injected with WT BM cells. Scale bars, 500 mm and 50 mm.
(F) Average chimerism in posttransplant Control-ER and Ezh1-KO-ER recipients analyzed by the contribution of donor-derived (CD45.1) cells to PB populations
(WBC, white blood cells). Data are means ± SD (n = 9).
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HSC Senescence Protection by Ezh1downregulated genes Cdc6, Runx1, and Mef2c, but not in the
promoters of p16INK4a, Bmp2, and Igfbp3 (Figure S4A). Interest-
ingly, the entire promoter regions of Cdc6, Runx, and Mef2cCellwere enriched for the H3K27me1 signal in Ezh1-KO cells,
whereas this signal was absent from the p16INK4a, Bmp2, and
Igfbp3 promoters. In contrast, the levels of H3K27me3 andStem Cell 11, 649–662, November 2, 2012 ª2012 Elsevier Inc. 657
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Figure 6. Ezh1 Maintains BM Homeostasis
(A) Enrichment scores for GO categories in the set of genes differentially expressed in Ezh1-deficient HSCs identified high percentage changes in genes
regulating HSC maintenance.
(B) Relative expression levels of selected transcripts (horizontal axis) from each GOcategory (A) measured by qRT-PCR in sorted HSCs (LSKCD150+CD48) from
Ezh1-KO and Control mice. Data are means ± SD from three replicates in Ezh1 null HSCs normalized to expression in Control HSCs (dashed line).
(C) Representative heat maps show the expression of genes with lymphoid-development, senescence-associated, and Polycomb-related functional annotations
that are significantly downregulated and upregulated in Ezh1mutant LSKCD150+CD48 cells. The rows correspond to genes and the columns to samples. Gene
expression values (relative to the mean expression in Control cells) are indicated on a log2 scale according to the color scheme shown.
(D) Venn diagram illustrating the overlap between genes downregulated and upregulated in these cells and genes with senescence-, lymphoid- and Polycomb-
related functional annotations according to the studies cited in the main manuscript.
See also Figure S4 and Table S2.
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HSC Senescence Protection by Ezh1bound Ezh2 and Bmi1 in the Cdc6, Runx, and Mef2c pro-
moters were not affected by the absence of Ezh1 (Figure S4A).
Furthermore, whereas Control HSCs showed site-specific
binding of Ezh1, Ezh2, and Bmi1 to the promoter regions of
p16INK4a (Bracken et al., 2007), Bmp2, and Igfbp3, binding
was absent from these upregulated genes in Ezh1-KO cells.
Comparable results were observed with the upregulated Ezh1-
target genes IL-6, Cdkn1a, and Zmat3 (data not shown). These658 Cell Stem Cell 11, 649–662, November 2, 2012 ª2012 Elsevier Indata support the view that the actions of Ezh2 and Bmi1 likely
require the presence of Ezh1, and that Ezh1-dependent repres-
sion induces monomethylation of H3K27 as the primary product
of the PRC2-Ezh1 reaction, with subsequent dimethylation. The
gene expression data thus correlate strongly with the hemato-
poietic phenotype of Ezh1-KO mice and suggest a mechanism
by which the histone methytansferase Ezh1 protects against
senescence.c.
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Figure 7. Recovery of Defective Hematopoiesis in Ezh1/Cdkn2a-TKO Mice
(A) qRT-PCR analysis of the expression of Ezh1, p16INK4a, ARF, Runx1, and Cdc6 mRNA in total HSCs (LSKCD150+CD48) from Ezh1/Cdkn2a-TKO mice
(Ezh1fl/fl;p16INK4a-ARFfl/fl;vavCretg/+). Results are standardized to b-actin and expressed relative to littermate Control-TKO mice (Ezh1fl/fl;p16INK4a-ARFfl/fl;
vavCre+/+). Data are means ± SD; n = 10, **p < 0.001, *p < 0.05).
(B) Absolute numbers of mature lymphoid (B220 and CD4/CD8) cells and total cellularity in spleen, thymus, and BM of Ezh1/Cdkn2a-TKO and Control-TKOmice.
Data are means ± SD (n = 5).
(C) Left: Representative FACS plots of BM cells, indicating mean percentages of the LSK populations, in Ezh1/Cdkn2a-TKO mice and Control-TKO littermates.
Right: Absolute numbers per femur of the LSK (LS+K+), CLP (LKlowSlowCD127+), and MP (LK+S) subpopulations. Data are means ± SD (n = 8).
(D) C12-fluorescein fluorescence histograms showing the relative levels of b-gal in LSK subpopulations from Control-TKO and Ezh1/Cdkn2a-TKO mice. The
values above the peaks are the median fluorescence intensities of the respective populations (n = 6).
(E) Contribution of donor-derived (CD45.2) cells from Ezh1/Cdkn2a-TKO and Control-TKOmice to PB populations in recipients at 4 weeks posttransplant (WBC,
white blood cells). Data are means ± SD (n = 7).
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HSC Senescence Protection by Ezh1Ezh1 Limits the HSC Senescence Response by
Repressing Cdkn2a
To test whether repression of Cdkn2a by Ezh1 is essential for its
antisenescence function, we generated Ezh1/Cdkn2a triple-
knockout (TKO) mice (Ezh1fl/fl;p16INK4a-ARFfl/fl;vavCretg/+) and
Control-TKO mice (Ezh1fl/fl;p16INK4a-ARFfl/fl;vavCre+/+) to condi-
tionally eliminate hematopoietic Cdkn2a expression in the Ezh1-
KO background (Figure 7A). Complete deletion of Ezh1 and
p16INK4a/ARF was not accompanied by significant compensa-Celltory upregulation of other Polycomb members (p < 0.05; Fig-
ure 7A; data not shown). We also observed altered HSC expres-
sion of the Ezh1 targets Runx1 and Cdc6 (Figure 7A). Total cell
numbers in BM, thymus, and spleen of Ezh1/Cdkn2a-TKO
mice were similar to numbers in Control-TKO littermates (Fig-
ure 7B), and mutant and Control mice also had similar propor-
tions of all major BM populations, including LSK, common
lymphoid progenitor (CLP), andMP stem/progenitor populations
(Figure 7C). The deletion of p16INK4a and ARF in Ezh1-KO HSCsStem Cell 11, 649–662, November 2, 2012 ª2012 Elsevier Inc. 659
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HSC Senescence Protection by Ezh1led to a near complete bypass of the senescence pathway
as determined by the decrease in the proportion of LSK cells ex-
hibiting SA-b-gal activity (4%–7% SA-b-gal+ cells, compared
with 5% in Control-TKO mice) (Figure 7D). To test the function-
ality of Ezh1/Cdkn2a-TKO HSCs, we generated competitive
chimeras. Remarkably, flow cytometry of PB in stably engrafted
chimeric mice showed that donor contribution to lymphocytes
declined slightly after 8 weeks without affecting PBmyeloid cells
(Figure 7E). In summary, these data suggest that removal of
p16INK4a and ARF from the Ezh1 null background rescues hema-
topoiesis by increasing proliferation and alleviating senescence
in the Ezh1-KO BM.
DISCUSSION
Chromatin modifiers such as the PcG proteins determine the
transmission of genetic information and regulate cell differentia-
tion. Disruption of PcG function prevents differentiation of ESCs
and correct embryonic development. The PRC2 methyltrans-
ferase Ezh2 was thought to be unique and essential for all
H3K27me3 marks in ESCs (Bernstein et al., 2006; Boyer et al.,
2006). However, its homolog Ezh1 is also indispensable for the
establishment of pluripotent cells and for the maintenance of
ESC self-renewal (Margueron et al., 2008; Shen et al., 2008).
Here we show that this dual requirement also holds true for
at least one population of somatic stem cells, the HSCs. The
extreme sensitivity of hematopoietic cells to Ezh1 inactivation
is remarkable when compared with the weaker impact of inacti-
vating its homolog Ezh2 in a similar system (Mochizuki-Kashio
et al., 2011; Su et al., 2003). Ezh1 deficiency severely reduces
the size of the adult HSC fraction and impairs the capacity of
HSCs for self-renewal and quiescence, effects not observed in
mice lacking Ezh2 (Mochizuki-Kashio et al., 2011). We thus
conclude that Ezh1 plays a dominant role among histone meth-
yltransferases in the maintenance of adult HSCs.
We show that in the hematopoietic system, where stem cell
activation is a transitory state that requires self-renewal coupled
with the prevention of differentiation and senescence, Ezh1
plays an unanticipated and critical role. Ezh1 protects primitive
hematopoietic cells from senescence by keeping them in a
slow-cycling state through its PRC2-associated Polycomb func-
tion. Deletion of Ezh1 profoundly compromises BM hematopoi-
esis, but not the self-renewal capacity of HSCs in FL. This
reflects the specialized function of Ezh1, which is mediated
through monomethylation and dimethylation of H3K27, thereby
preventing proliferation and repressing pathways required for
terminal differentiation and senescence of adult HSCs. Our
data suggest that Ezh1-deficient cells exhibit delayed lympho-
cyte differentiation at specific stages of hematopoiesis, and it
may be that this effect arises from the reduced size of the prim-
itive HSC population.
Epigenetic mechanisms, including DNA methylation and his-
tone modification, are important regulators of gene expression
in senescence. The initial challenge in revealing Ezh1-mediated
regulation of gene expression was to determine what Ezh1 target
genes do. Through genome-wide array analyses combined with
quantitative ChIP assays, we have examined epigenomic and
gene expression changes induced by Ezh1 deletion in senesced
HSCs. Our results identify a coordinated methylation of the660 Cell Stem Cell 11, 649–662, November 2, 2012 ª2012 Elsevier Inrepressive H3K27 mark, which activates the master senescence
regulator Bmp2 (Kaneda et al., 2011) and selectively represses
expression of Runx1 and Cdc6, which regulate critical hemato-
poietic processes (Swiers et al., 2010). Our results reveal dy-
namic and harmonized H3K27me1 and H3K27me2 alterations,
repression of Runx1 without gain of H3K27me3, and selective
activation of downstream target genes, such as Smad1, that
may contribute to growth arrest (Kaneda et al., 2011). Despite
this broad association of H3K27me1 H3K27me2 with silenced
genes in different tissue lineages, loss of Ezh1-mediated repres-
sion reduces the proliferation of these lineages by upregulating
the Cdkn2a locus, and tempers acquisition of the senescence
barrier. Indeed, deletion of the p16INK4a/p19ARF locus rescues
the HSC defects in these mice. Our findings underline the
importance of epigenetic changes in the regulation of the criti-
cal physiological barrier to inducing the senescence that blocks
oncogenic transformation. Further understanding of how PRC2-
Ezh1 maintains specific gene-expression patterns may come
from consideration of overall chromatin structure, an essential
issue that has garnered attention in the context of ESC differen-
tiation (Margueron and Reinberg, 2011).
Ezh1 and Ezh2 proteins are implicated in H3K27 monomethy-
lation, dimethylation, and trimethylation, with each methylated
form likely to be functionally distinct. The regulation of the level
of H3K27 methylation is, however, unknown. The answer may
lie in the particular protein composition of PRC2 complexes.
For example, Suz12 has been found to be essential for
H3K27me3, but dispensable for H3K27me1 (Pasini et al., 2004).
Similarly, the mammalian protein PHF1, a Drosophila PCL
homolog, associates with PRC2 components and stimulates
formation of H3K27me3 in vitro and in vivo (Cao et al., 2008).
Our work suggests that H3K27me1 plays a critical role in main-
taining heterochromatin condensation and gene silencing, a
mechanism reminiscent of the silencing imposed by two Arabi-
dopsis histone methyltransferase genes, ATXR5 and ATXR6
(Jacob et al., 2010). It remains unknown, however, how this
histone modification signals such events. One possibility is
that H3K27me1 simply recruits an H3K27me1-binding protein.
Alternatively, monomethylation of H3K27 (and possibly further
H3K27me2 and H3K27me3 modifications) may act in a negative
manner, either by preventing unmethylated H3K27-interacting
proteins from binding chromatin or by blocking alternative his-
tone modifications to H3K27. We thus suggest that H3K27me1
is an important intermediary PRC2-Ezh1 product, since it not
only constitutes the substrate for subsequent H3K27me2, but
also prevents H3K27 acetylation. In fact, our results, while vali-
dating only a small proportion of Ezh1-regulated transcripts,
shed light on this matter, and demonstrate the binding of Ezh1,
Ezh2, and Bmi1 to upregulated Igfbp3, IL-6, Cdkn1a, Zmat3,
Bmp2, and p16INK4a transcripts in WT HSCs (Bracken et al.,
2007). The action of Ezh1 might thus involve other chromatin
targets, such as Bmi1 or Ezh2, enabling fine regulation of cell
specification processes. These data provide a starting point for
further studies to uncover the underlying mechanisms of Ezh1-
mediated hematopoiesis.
Our results imply that Ezh1-regulated senescence ability is a
limiting factor in the maintenance of functional HSC reserves.
It thus seems plausible that some of the decline in HSC re-
constituting potential associated with defective self-renewal inc.
Cell Stem Cell
HSC Senescence Protection by Ezh1Ezh1-KOmice could be due to senescence, rather than genomic
damage or telomere erosion. Loss of HSC potential might be
mediated by activation of senescence or cytostatic tumor
suppressor pathways at cell-cycle checkpoints, leading to dele-
tion or growth arrest of defective progenitor clones.
On the basis of our results, we propose that Ezh1 regulates
the balance between HSC maintenance and a protective senes-
cence response to prevent uncontrolled proliferation. Abundant
evidence indicates that cell senescence is a natural physio-
logical protection against tumor development, and therapeutic
engagement of senescence may present a valuable treatment
strategy for cancer. Targeting the PRC2-Ezh1 complex is an
attractive approach to the manipulation of these intrinsic senes-
cence pathways. The ability to promote senescence induction
upstream of Cdkn2a is likely to have a substantial therapeutic
effect, especially given the frequent mutations that inactivate
these pathways. Understanding molecular mechanisms by
which Ezh1 affects stem cell fate will provide new insights into
HSC biology and will also increase understanding of leukemic
transformation, with the potential to facilitate eradication of
leukemic stem cells.
EXPERIMENTAL PROCEDURES
Mice
Generation and analysis of ckoEzh1fl/+ mice is detailed in the Supplemental
Information. The vavCre and Rosa26-Cre-ERT2 mouse lines were maintained
after backcrossing to C57BL/6 over two generations, and were crossed with
ckoEzh1fl/fl mice to generate Ezh1-KO (Ezh1fl/fl/vavCretg/+), Control (Ezh1fl/fl/
vavCre+/+), Ezh1-KO-ER (Ezh1fl/fl-CreERtg/tg) and Control-ER (Ezh1+/+-
CreERtg/tg) mice. All genotyping primers are listed in Table S1. ckop16INK4a/
ARFfl/fl mice, kindly provided by Anton Berns, were crossed with Ezh1-KO
mice to generate Ezh1/Cdkn2a-TKO and Control-TKOmice. Additional details
are provided in the Supplemental Experimental Procedures.
Transplantation Assays
Cells were transplanted (via retro-orbital injection) into the congenic CD45.1+
B6.SJL mouse strain, and hosts were monitored for the presence of CD45.2+
donor-derived cells. Engraftment efficiency in recipients was monitored by
FACS analysis of the contribution of donor CD45.1-positive cells to PB popu-
lations at 8 weeks posttransplant. Additional details are provided in the
Supplemental Experimental Procedures.
Flow Cytometry, Cell Sorting, ChIP Assays, Protein Analysis, and
Immunohistochemistry
Details are described in the Supplemental Experimental Procedures.
Statistical Analysis
Computational processing of experimental data is described in the Supple-
mental Information. All data are expressed as means ± SD. Statistical signifi-
cance of differences was measured by unpaired two-tailed Student’s t test;
*p < 0.05, or **p < 0.001.
ACCESSION NUMBERS
A complete list of the differentially expressed genes in Ezh1-KO HSCs has
been deposited in the Gene Expression Omnibus under accession number
GSE36288.
SUPPLEMENTAL INFORMATION
Supplemental Information for this article includes four figures, four tables, and
Supplemental Experimental Procedures and can be found with this article
online at http://dx.doi.org/10.1016/j.stem.2012.08.001.CellACKNOWLEDGMENTS
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